IL1F10 and synovial sarcoma: The latest molecular-based study conducted on the role of IL-38 in SS introduced IL-38 as an inhibitory agent for the secretion of chemokines involved in the TH17 signaling pathway, preventing the exacerbation of immunopathophysiology involved in pSS, and acting as a promising targeted immunotherapeutic-based treatment for patients with pSS [146].